Why CBD still cannot be sold as a dietary supplement

A persistent misreading of the 2018 Farm Bill is that it legalized CBD as a consumer ingredient. It did not. It removed hemp from the Controlled Substances Act. What CBD may lawfully be sold as is a separate question, decided by a different agency under a different statute - and the answer has been no for years.

The drug exclusion clause

The Federal Food, Drug, and Cosmetic Act contains a provision usually called the drug exclusion clause. In simplified terms: if a substance has been approved as a drug, or has been the subject of substantial public clinical investigations as a drug, it generally may not then be introduced into food or marketed as a dietary supplement.

In June 2018, the FDA approved Epidiolex, the first drug containing CBD derived from the cannabis plant. Because CBD is the active ingredient in an approved drug and was the subject of clinical investigation before being marketed as a food or supplement, the FDA has determined that CBD may not be marketed in or as a dietary supplement, and may not be added to food sold in interstate commerce.

Note the sequence. Epidiolex was approved months before the 2018 Farm Bill passed. The supplement pathway was closed before hemp was descheduled.

The FDA’s own position: the existing frameworks do not fit

Rather than force CBD through the supplement or food pathway, the FDA has concluded that a new regulatory pathway is needed - one balancing access against oversight. It has cited safety questions that it says the existing frameworks are not built to manage, particularly with long-term use: potential liver harm, interactions with certain medications, and possible effects on the male reproductive system.

Alongside that conclusion, the agency denied citizen petitions asking it to conduct rulemaking that would allow CBD to be marketed as a dietary supplement, and said it is prepared to work with Congress on a purpose-built framework.

What sellers do in the meantime

The gap between the legal position and the retail reality is wide and well known. In practice, most consumer CBD is sold into that gap, and enforcement has concentrated on the clearest violations rather than the category as a whole - most consistently against health claims. Marketing a product as treating, preventing, or curing a disease turns it into an unapproved new drug and is the fastest route to a warning letter, regardless of what the product actually contains.

Which is why the operative compliance advice for sellers has been stable for years even as the statutory picture has not:

• Do not make disease claims. Not in copy, not in testimonials you republish, not in the meta description.
• Do not imply supplement status with structure/function language borrowed from the supplement aisle.
• Keep batch-specific third-party certificates of analysis available, and make sure the label matches them.

Why this matters more after November

The definitional change taking effect on November 12, 2026 narrows what counts as hemp and caps total THC in finished products. It does not touch the drug exclusion clause, and it does not create a supplement pathway for CBD.

So the two constraints now stack. A product can be fully compliant with the new hemp definition and still have no lawful route to market as a dietary supplement. Anyone reading the November change as a reset of the FDA question is reading the wrong statute.

Congressional action remains the only route that resolves it. Trade groups have been asking for exactly that for years, so far without a bill reaching the finish line.

• #fda
• #supplements
• #regulation